New antineoplastic drugs and their proper use.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008099:Liver / Q000187:drug effects; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D001761:Bleomycin; D003606:Dacarbazine; D004317:Doxorubicin; D001215:Asparaginase; D001374:Azacitidine